Dataset from Phase 2 Study Of The Effects Of Open-Label CP-690,550 And Double-Blind Atorvastatin On Lipids In Patients With Active Rheumatoid Arthritis

All patients will be in instructed to eat a therapeutic lifestyle diet and will receive
CP-690,550 throughout the 12 weeks of this study. After 6 weeks, half will receive the
cholesterol lowering agent, atorvastatin, and half a matching placebo. This study will first
measure the effects of CP-690,550 on cholesterol levels and then the effects of adding
atorvastatin on those levels.